Catalyst Clinical Research
Andrew Zupnick, PhD, currently serves as Vice President of Oncology Drug Development at Catalyst Clinical Research, LLC since May 2020. Previously, Andrew Zupnick held positions as Vice President of Oncology Strategy at IQVIA and Novella Clinical, reflecting extensive experience in oncology strategy and business development. Andrew Zupnick's career began at Prologue Research, where roles progressed from Marketing Manager to Director of Business Development & Marketing before the company's acquisition by Novella Clinical. Educational qualifications include a Bachelor of Science in Biology from the Massachusetts Institute of Technology and a Doctorate in Cell and Molecular Biology from Columbia University, with research focused on the p53 tumor suppressor.
This person is not in any offices
Catalyst Clinical Research
2 followers
Catalyst Clinical Research is a provider of clinical operation solutions to the biotechnology, pharmaceutical and medical device companies. The company was built on more than two decades of experience in assisting clients with their clinical development programs by providing therapeutically-aligned experts and teams and customized solutions.